Pharma News

Union Minister for Chemicals and Fertilizers Shri Mansukh Mandaviya launched NIPER Research Portal along with Shri Bhagwanth Khuba, Minister of State for Chemicals and Fertilizers in presence of Dr V. K Paul, Member (Health), Niti Aayog. National Institute of Pharmaceutical Education and Research (NIPER) Research Portal has been created with the aim to disseminate the information about all the NIPERs and their research activities, patents filed and Publication information at one place so that a industry and other stakeholders know about them.

An Engagement Coordination and Arrangement (ECA) on Maternal, Adolescent, Child care and Nutrition in Kolhan division in Jharkhand between National Health Mission, Tata Steel Foundation and American India Foundation under the flagship project MANSI+ (Maternal and Neonatal Survival Initiative+) was signed today at the office of National Health Mission (NHM), Ranchi.

Sun Pharma Canada Inc Limited announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease. CEQUA (cyclosporine ophthalmic solution 0.09% w/v), a calcineurin inhibitor immunomodulator, is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration.

Once you know how it works for one disease, immuneML can make diagnostic tools for other types of diseases as well.

Different diseases have different methods for testing if a person has the disease or not. immuneML, a new open source machine learning platform, can potentially look for a lot of diseases in just one blood sample.

Patients under immunosuppressive therapy, who do not respond to primary COVID-19 vaccination, have an increased risk for severe COVID-19 disease courses. Until now, it was not clear whether those patients at risk can benefit from an additional booster vaccination. Recent research findings from MedUni Vienna show that a third vaccination is safe and effective in those patients who were initially unable to produce antibodies after vaccination. The study was recently published in the acclaimed journal "Annals of the Rheumatic Diseases".

 IPC organised the virtual training on Pharmacovigilance for NABH Accredited Hospitals in India on 21st January 2022. The Training Programme was intended to provide a platform for the NABH-Accredited Hospitals to understand the systems and procedures involved in ADR-reporting and relevant practises.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg, the generic version of Ziac®1 Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg, of Teva Branded Pharmaceutical Products R&D, Inc.

BioLife Sciences is pleased to announce that it has entered into exclusive negotiations with Health Box LLC, an Arizona-based company which provides a diverse mix of advanced orthomolecular and natural health products founded in - extensive research focused on medicinal botanicals, micronutrients, dietary supplements, proprietary herbal blends, and apothecary style subscription services.

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.